版本:
中国

BRIEF-Newlink Genetics says Roche Group member Genentech informed co that it intends to return rights to IDO inhibitor GDC-0919

June 8 Newlink Genetics Corp

* Newlink Genetics - on June 6, Genentech, a member of Roche Group, informed co that it intends to return rights to IDO inhibitor GDC-0919

* Newlink Genetics - rights co had licensed to genentech with respect to GDC-0919 will revert to co when termination becomes effective

* Newlink Genetics - research collaboration with Genentech for discovery of next generation IDO/TDO (tryptophan 2,3-dioxygenase) inhibitors continues Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐